SARMs

ACP-105

An experimental androgen-receptor modulator with rat pharmacology and human metabolism research; detecting a compound is different from proving a benefit.

Preclinical pharmacology plus human analytical metabolism; no efficacy trial in these sources

ACP-105 molecular structure — Structure reference · C16H19ClN2O

Practical use

Evidence interpretation and clinical context

Identify the study’s purpose: Separate metabolism and detection research from trials that measure patient outcomes.
Keep species visible: Attach rat to any anabolic claim based on the discovery study.
Ask what remains unmeasured: A credible summary identifies missing clinical benefit and long-term safety endpoints.

Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators.

A multivariate data analysis approach for the investigation of in vitro derived metabolites of ACP-105 in comparison with human in vivo metabolites.

Regulatory status — primary or official source

Overview

ACP-105 is a nonsteroidal selective androgen-receptor modulator. Its discovery research examined whether androgen signaling could favor muscle-related effects over reproductive tissues. That research question does not establish a safe performance-enhancing medicine.

Risks and limitations

The cited human work was designed to identify metabolites, not establish therapeutic safety. It cannot quantify liver, cardiovascular, fertility or long-term endocrine risks. FDA also warns of serious harms associated with the SARM class.

How to read this

A metabolism study can confirm that a substance was processed by the body without measuring strength, muscle growth or patient benefit. This distinction is especially important when a reference list is advertised as human evidence.

Research explained

Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators.

Who was studied

Laboratory receptor experiments and short-term studies in castrated male rats.

What was found

ACP-105 behaved as a partial androgen-receptor agonist and produced anabolic effects in the rat model, with a different tissue-response pattern from testosterone.

What it cannot establish

Castrated rats are an androgen-deficient experimental model. Organ-weight responses do not establish athletic performance, chronic toxicity or a clinical advantage in people.

Read the original study

A multivariate data analysis approach for the investigation of in vitro derived metabolites of ACP-105 in comparison with human in vivo metabolites.

Who was studied

Laboratory liver preparations and urine collected after a human exposure.

What was found

Researchers characterized ACP-105 metabolites to improve analytical identification.

What it cannot establish

This was analytical research. It did not test hypertrophy, function, a treatment indication or a safe pattern of human use.

Read the original study

Regulatory status

FDA states that SARMs are unapproved drugs, not dietary supplements.

Supporting source

What selective means here

Selectivity describes the relative response of tissues under the experiment’s conditions. It is not a claim that only muscle responds or that hormonal feedback is unaffected.

Supporting source